Abstract：
Seventy percent of breast cancer patients have an active estrogen receptor. Tamoxifen interferes with estrogen\'s ability to bind to cancer cells. The most challenging aspect of tamoxifen, however, is that breast cancer cells become resistant to its effects. Some studies have shown that alterations in miRNA expression contribute significantly to drug resistance in breast cancer. Therefore, the present systematic review aims to investigate miRNAs that significantly influence the response to tamoxifen treatment. The present study follows the PRISMA instructions. The Web of Science, PubMed, and Scopus databases were searched to retrieve English articles. The searches were conducted up to September 11, 2022. The search strategy included the terms \"Tamoxifen\", \"Breast Neoplasm\", and \"MicroRNA\". The inclusion criteria of this study are English, original, and experimental studies investigating miRNAs that are effective in the treatment efficacy of tamoxifen. A total of 565 articles were retrieved. After screening, 75 studies met our inclusion criteria. This systematic review study examined 105 miRNAs, of which 44 have a positive effect, and 47 miRNAs inhibit tamoxifen function. Fourteen miRNAs have a controversial effect, ie, some studies show positive and negative effects. The study of miRNAs affecting tamoxifen function in breast cancer patients may facilitate the identification of individuals at higher risk of disease recurrence. Conversely, it can potentially utilize appropriate interventions to defeat drug resistance effectively.
摘要：
70%的乳腺癌患者有一个活跃的雌激素受体。他莫昔芬干扰雌激素与癌细胞结合的能力。他莫昔芬最具挑战性的方面，然而,乳腺癌细胞对其作用产生了抗性。一些研究表明，miRNA表达的改变对乳腺癌的耐药性有重要贡献。因此,本系统综述旨在研究显著影响他莫昔芬治疗反应的miRNAs.本研究遵循PRISMA说明。WebofScience,PubMed,搜索Scopus数据库以检索英语文章。搜索一直进行到2022年9月11日。搜索策略包括术语“他莫昔芬”，“乳腺肿瘤”，和“MicroRNA”。这项研究的纳入标准是英语，原创,以及研究对他莫昔芬治疗效果有效的miRNA的实验研究。共检索到565篇文献。筛选后,75项研究符合我们的纳入标准。这项系统综述研究检测了105个miRNAs，其中44项有积极作用，和47种miRNA抑制他莫昔芬功能。14个miRNAs有争议的作用，ie,一些研究显示了积极和消极的影响。对影响乳腺癌患者他莫昔芬功能的miRNA的研究可能有助于鉴定疾病复发风险较高的个体。相反，它可以潜在地利用适当的干预措施来有效地战胜耐药性。
